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OBJECTIVES The goal of this study was to evaluate the mortality benefit of beta-blockers after successful
percutaneous coronary intervention (PCI).
BACKGROUND Beta-blockers reduce mortality after myocardial infarction (MI), though limited data are
available regarding their role after successful PCI.
METHODS Each year from 1993 through 1999, the first 1,000 consecutive patients undergoing PCI were
systematically followed up. Patients presenting with acute or recent MI, shock, or unsuc-
cessful revascularization procedures were excluded from the analysis. Clinical, procedural, and
follow-up data of beta-blocker-treated and non-beta-blocker-treated patients were compared.
A multivariate survival analysis model using propensity analysis was used to adjust for
heterogeneity between the two groups.
RESULTS Of the 4,553 patients, 2,056 (45%) were treated with beta-blockers at the time of the
procedure. Beta-blocker therapy was associated with a mortality reduction from 1.3% to 0.8%
at 30 days (p  0.13) and a reduction from 6.0% to 3.9% at one year (p  0.0014). This
survival benefit of beta-blockers was independent of left ventricular function, diabetic status,
history of hypertension, or history of MI. Using propensity analysis, beta-blocker therapy
remained an independent predictor for one-year survival after PCI (hazard ratio, 0.63; 95%
confidence interval, 0.46 to 0.87; p  0.0054).
CONCLUSIONS Within this large prospective registry, beta-blocker use was associated with a marked
long-term survival benefit among patients undergoing successful elective percutaneous
coronary revascularization. (J Am Coll Cardiol 2002;40:669–75) © 2002 by the American
College of Cardiology Foundation
Numerous secondary prevention trials have shown that
beta-blockers prevent death and reduce the risk of re-
infarction after myocardial infarction (MI) (1–10). How-
ever, most of these studies were carried out before the
reperfusion era. The role of beta-blockers after successful
reperfusion therapy or revascularization procedures has not
been well defined. While it is hoped that revascularization
reduces the need for anti-anginal medications, the use of
these medications was found to be highly prevalent at six
months after percutaneous coronary intervention (PCI) in
clinical practice (11). By contrast with the past, when PCI
and medical therapy had been considered as competitive
strategies for symptomatic coronary artery disease (CAD)
(12,13), we hypothesized that beta-blockers might provide
complementary benefit after successful revascularization.
Hence, we examined the effect of beta-blockers on mortality
after PCI in a large registry and sought to define patient
characteristics that might benefit from this class of medica-
tion.
METHODS
Patient selection. Each year from January 1993 through
June 1999, we prospectively followed up the first 1,000
consecutive U.S. residents who underwent PCI at the
Cleveland Clinic Foundation. The demographic and pro-
cedural data, including medication use, hemodynamic sta-
tus, equipment use, and final results of each case were
prospectively recorded in an interventional database. Serum
creatine kinase (CK) was drawn routinely at 8 h and 12 to
24 h after each case, and if CK was 100 mg/dl, CK-MB
levels would be obtained in the same blood sample. Clinical
event data during the index hospitalization, at 30 days and
at one year were collected by cardiology nurses and research
coordinators through patient interview, chart review, and
serial telephone contacts. Mortality data were confirmed
with the United States Social Security Administration
Death Master File. Patients were divided into two groups
according to whether beta-blocker therapy was being re-
ceived at the time of PCI procedures. Patients who pre-
sented with acute MI, recent (7 days) MI, cardiogenic
shock, or failure of revascularization (final residual stenosis
of target lesions 20% after stenting or 50% after balloon
angioplasty, final TIMI [Thrombolysis in Myocardial In-
farction] flow grade 3, or ongoing ischemia) in the index
procedure were excluded from the analysis.
To correlate the prevalence of pre-procedural beta-
blocker use with that at the time of discharge, we sampled
the first 20 cases performed at the beginning of each year
within the study period; hence, a total 140 cases were
reviewed.
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Statistical analysis. Continuous variables were expressed
in means  SD, and they were compared by means of
Student t test or Mann-Whitney rank sum test. Categorical
data were displayed as frequencies and percentages. Chi-
square test was used for bivariate analysis for categorical
data. Kaplan-Meier estimation and Cox proportional haz-
ards modeling were used for unadjusted and adjusted
survival analysis, respectively.
To attempt to adjust for the bias inherent in the decision
about beta-blocker therapy before PCI, propensity analysis
was performed (14,15). Propensity analysis aims to identify
patients with similar probability of receiving beta-blocker
therapy based on the observed clinical characteristics. Using
a multivariable logistic regression model that includes the
baseline characteristics as the independent variables, the
probability of being assigned to beta-blocker therapy was
determined. The variables that were included in the pro-
pensity score model were: age; gender; body mass index;
presentation with unstable angina (angina at rest 20 min,
new onset angina 2 months, angina severity equal to or
greater than Canadian Cardiovascular Society classification
class III, or acceleration of angina 1 class within two
months); identification of positive ischemia on stress test
(electrocardiographic, nuclear scintigraphic, or echocardio-
graphic criteria); presence of congestive heart failure (New
York Heart Association class II to IV); diabetes; hyperten-
sion; hypercholesterolemia; current cigarette smoking; renal
insufficiency (serum creatinine 2.0 mg/dl); peripheral
vascular disease; chronic obstructive lung disease (COPD);
history of MI, stroke, or coronary bypass surgery (CABG);
restenotic lesions; premature CAD (onset 45 years in
males or 55 years in females); use of aspirin, angiotensin-
converting enzyme (ACE) inhibitors, statins, calcium-
channel receptor blockers, diuretics, or anti-arrhythmics;
left ventricular ejection fraction (LVEF); number of dis-
eased coronary arteries; and the years of intervention (1993
to 1994, 1995 to 1996, 1997 to 1999).
The population was then divided into deciles according to
the propensity score. Within each decile, the mean propen-
sity scores of the beta-blocker and non-beta-blocker groups
were compared, as well as their clinical and procedural
characteristics. To adjust for the heterogeneity between the
two groups, the propensity score was then entered as a
continuous variable in the Cox proportional hazards model,
along with 34 potential covariates. These covariates in-
cluded the baseline variables entered in the propensity score
model and other procedural variables that might correlate
with outcome, namely, lesion morphology (type A/B1 vs.
B2/C), left anterior descending or saphenous vein graft
intervention, number of vessels intervened, type of contrast
(ionic vs. non-ionic), stent use, and glycoprotein IIb/IIIa
inhibition. All statistical analyses were performed with the
SAS program (version 6.12, SAS, Cary, North Carolina).
RESULTS
Baseline characteristics. During the study period, a total
of 6,558 patients were followed up, and, of these, 4,553
patients were eligible for study entry. Of these, 2,056
patients (45.1%) were receiving a beta-blocker before the
procedure. Table 1 shows the baseline characteristics ac-
cording to beta-blocker treatment. There were important
differences between the two groups. Patients who were
receiving beta-blocker therapy before coronary intervention
were younger, more likely to be female and more likely to
have hypercholesterolemia, hypertension, prior MI, con-
comitant statin therapy, multi-vessel CAD, and more likely
to present with unstable angina. They were less likely to
receive ACE inhibitors, calcium-channel blockers, diuretics,
and anti-arrhythmics. At the procedure, beta-blocker recip-
ients were more likely to receive stents and ionic contrast.
The prevalence of diabetes, renal insufficiency, prior coro-
nary bypass surgery, history of stroke, location of lesion,
glycoprotein IIb/IIIa antagonist use, and number of vessels
being intervened were similar between the two groups.
Unadjusted 30-day and one-year all-cause mortality. As
depicted on the Kaplan-Meier curve (Fig. 1), receiving a
beta-blocker at the time of the procedure was associated
with a trend toward an early (30-day) survival benefit (0.8%
vs. 1.3%, hazard ratio  0.62, log-rank p  0.13), and the
mortality difference continued to widen through the end of
the first year (3.9% vs. 6.0%, hazard ratio  0.65, log-rank
p  0.0014).
Propensity analysis. Within the propensity score analysis,
variables that predicted the prescription of beta-blocker
before PCI were (in descending order): concomitant statin
therapy, hypertension, presentation with unstable angina,
and prior MI (Table 2). On the other hand, independent
predictors against a prescription of beta-blocker included (in
descending order) concomitant anti-arrhythmic agents,
calcium-channel antagonist, COPD, ACE-inhibitor use,
LVEF 35%, congestive heart failure, positive stress test,
and male gender. The goodness of fit of the propensity score
was given by the c statistic (or area under the receiver
operating characteristic curve) being 0.68. Within each
decile of the study population, the propensity scores and
baseline characteristics were similar among the beta-
blocker-treated and non-beta-blocker-treated groups.
Multivariate analysis of six-month mortality. Using Cox
proportional hazards model to adjust for all potential
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CABG  coronary artery bypass grafting
CAD  coronary artery disease
CI  confidence interval
CK  creatine kinase
COPD  chronic obstructive pulmonary disease
LVEF  left ventricular ejection fraction
MI  myocardial infarction
PCI  percutaneous coronary intervention
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variables, beta-blocker therapy at the time of PCI remained
an independent predictor for survival at one year (hazard
ratio  0.62, 95% confidence interval [CI]: 0.45 to 0.87,
p  0.0048) (Table 3). When the propensity score was
included in the model with all the covariates to adjust also
for the chance of prescription of beta-blocker, the effect of
beta-blocker pre-treatment on one-year survival did not
change significantly (hazard ratio  0.63, 95% CI: 0.46 to
0.87, p  0.0054). Other predictors for mortality are listed
in Figure 2. Diabetes, age 75 years, triple-vessel CAD,
poor left ventricular (LV) systolic function, diuretic use,
COPD, renal insufficiency, and low body mass index were
independent predictors for mortality at one year. Aspirin use
at the time of procedure was associated with survival benefit
at one year.
Subgroup analysis. The mortality benefits among sub-
groups are shown in Figure 3. Of note, beta-blocker therapy
was associated with a survival benefit in most of the
subgroups, except for patients who underwent successful
PCI for single-vessel CAD (Breslow-Day test for single-
vessel vs. multi-vessel CAD, p value  0.067). In addition,
beta-blocker therapy was shown to be associated with a
marked survival benefit among patients with renal insuffi-
ciency (Breslow-Day test for renal insufficiency vs. preserved
renal function, p  0.049). Despite a relatively small
number of patients treated with rotational atherectomy, a
significant survival benefit was associated with beta-blocker
treatment. On the other hand, beta-blocker use did not
prevent peri-procedural myonecrosis (defined as total CK or
CK-MB fraction1 upper normal limit in two sequential
samples, 15.5% vs. 15.3%, p  NS), or peri-procedural MI
(defined as total CK or CK-MB fraction 3 times the
upper normal limit in 2 sequential samples, 4.1% vs. 5.1%,
p  NS).
Pre-procedural beta-blocker use and use at the time of
discharge. Among the 140 cases that were sampled, 73 of
80 patients who were receiving beta-blockers at the time of
the procedure were discharged also receiving beta-blockers,
and 52 of 60 patients not pre-treated with beta-blockers
were not discharged with beta-blockers. Hence, there was
an 89% correlation of pre-procedural beta-blocker use and
use of beta-blocker after discharge.
DISCUSSION
Within this large prospective interventional registry, beta-
blocker therapy was associated with an early mortality
reduction after successful elective PCI, and the benefit
increased during the first year of follow-up. This treatment
effect was present to a similar extent across the majority of
the subgroups regardless of age, diabetic status, history of
MI, lesion type, or LV systolic function. In addition to the
patients who had a history of MI, a striking survival benefit
was also found in patients with renal insufficiency and those
who underwent multi-vessel PCI. Importantly, the mortal-
ity benefit of beta-blockers observed at one year was
independent of peri-procedural MI. Furthermore, beta-
blockers offered no protection against peri-procedural MI.
Table 1. Baseline Characteristics and Procedural Data of the
Patients at the Time of PCI
Characteristics
Beta-Blocker
(n  2,056)
No
Beta-Blocker
(n  2,497)
Age (yrs)* 62.9  11.0 64.1  10.4
Female (%)* 30 25
Body mass index (kg/m2) 30.9  9.6 28.7  9.1
Heart rate (beats/min)* 69.3  13.1 73.7  13.2
Risk factors
Current smoker (%) 17 15
Diabetes mellitus (%) 27 27
Hypercholesterolemia (%)* 51 45
Hypertension (%)* 66 57
Premature CAD (%) 30 30
Comorbidity
Prior MI (%)* 47 41
Prior coronary bypass surgery (%) 35 32
History of congestive heart failure (%)* 7.4 11
NYHA class I/II/III/IV 3.5/2.5/0.7/0.7 4.0/3.5/2.3/1.6
Renal insufficiency (%) 3.9 4.2
Peripheral vascular disease (%)* 7.1 8.8
Prior stroke (%) 8.4 7.7
Chronic obstructive lung disease (%)* 3.7 8.3
Medications
Aspirin (%) 96 95
ACE inhibitor (%)* 16 20
Calcium-channel blocker (%)* 34 52
HMG-CoA reductase inhibitor (%)* 32 22
Diuretic (%)* 16 18
Antiarrhythmia (%)* 1.4 3.3
Positive stress test* 42 58
Procedural profile
Unstable angina (%)* 73 65
LVEF 35 (%)* 8.3 11
Number of diseased vessels
(50% severity) (%)*
1 34 37
2 31 31
3 35 32
Lesion location (%)
LAD 42 43
RCA 36 36
Circumflex 35 35
Number of vessels treated (%)
1 85 85
2 13 14
3 0.7 0.7
Restenotic lesion(s) (%) 19 20
SVG intervention (%) 13 11
Ionic contrast (%)* 77 73
Stent(s) (%)* 45 41
GP IIb/IIIa antagonist (%) 48 48
Peri-procedural MI
CK-MB  1x upper limit of normal 15 15
CK-MB  3x upper limit of normal 4.1 5.1
*p  0.05.
ACE  angiotensin-converting enzyme; CAD  coronary artery disease; CK 
creatine kinase; GP  glycoprotein; HMG-CoA  3-hydroxy-3-methylglutaryl–
coenzyme A; LAD  left anterior descending; LVEF  left ventricular ejection
fraction; MI  myocardial infarction; NYHA  New York Heart Association;
PCI  percutaneous coronary intervention; RCA  right coronary artery; SVG 
saphenous vein graft.
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Comparison with other beta-blocker and MI studies.
The effect of beta-blockade for the secondary prevention of
MI has been established in numerous studies (1–10).
Mortality reduction with beta-blockade after acute MI is
mainly mediated by its negative chronotropic and inotropic
effects, leading to reduction of arterial blood pressure,
reduction of myocardial oxygen demand, and anti-
arrhythmogenesis. Overall, mortality rates were reduced by
25% to 35% within the first year in these trials. Most of
these studies were performed before the widespread use of
fibrinolytics or PCI for reperfusion therapy. The use of
beta-blockers after successful percutaneous revascularization
has not been addressed in the American College of Cardi-
ology/American Heart Association clinical guidelines. The
importance of the appropriate medical therapy after PCI
may be less emphasized in the modern era when procedure-
oriented strategies receive substantial attention. Using the
data from a large interventional database, this analysis
suggests a mortality benefit and reinforces the utility of
beta-blockers after elective revascularization. By contrast
with the clinical trials in which a mortality benefit with
beta-blockers was confined to patients with prior MI, our
study observed a benefit extending to patients who did not
have a history of MI. Similar to the study by Sharma et al.
(16), our study concluded that the mortality reduction at
one-year was not mediated by the cardioprotection within
the subgroup of patients who had peri-procedural MI.
However, by contrast with the same study, our data did not
detect a cardioprotective effect against peri-procedural MI
with beta-blockade (17).
Observation from subgroup analyses. Consistent with
studies about beta-blockade in high-risk populations (18–
21), survival benefits were also found in patients whose
conditions would be considered a contraindication for this
therapy 20 years ago, such as ischemic cardiomyopathy,
diabetes, and presence of peripheral vascular disease. Fur-
thermore, this benefit was present regardless of the type of
diabetes. Interestingly, our study revealed a striking mortal-
ity benefit of beta-blockers in patients with renal insuffi-
ciency, an observation that is contrary to the previously held
belief that these agents reduced cardiac output, leading to a
reduction in renal blood flow and glomerular filtration rate
(22). Conversely, renal impairment is associated with
chronic hypertension, diabetes, presence of peripheral vas-
cular disease, multi-vessel CAD, and LV dysfunction (23),
and these factors were linked to benefits from beta-blockers
Table 2. Factors Associated With the Propensity of Beta-
Blocker Prescription
Factors Odds Ratio p Value
More likely prescribed with beta-blocker
Statin 1.58 0.0001
Hypertension 1.54 0.0001
Unstable angina 1.47 0.0001
Prior MI 1.40 0.0001
Year 1995–1996 1.39 0.0001
Less likely prescribed with beta-blocker
Anti-arrhythmic agents 2.68 0.0001
Calcium-channel blocker 2.48 0.0001
Chronic obstructive lung disease 2.20 0.0001
Congestive heart failure 1.80 0.0004
ACE inhibitor 1.59 0.0001
Left ventricular ejection fraction 35% 1.37 0.0001
Positive stress test 1.24 0.0027
Male 1.18 0.0320
Area under ROC curve (c-statistic) 0.68
ACE  angiotensin-converting enzyme; MI  myocardial infarction; ROC 
receiver operating characteristic.
Table 3. Survival Benefit Associated With Beta-Blocker Use
After PCI
Hazard Ratio 95% CI p Value
Unadjusted 0.64 0.49–0.84 0.0015
Adjusted for covariates 0.62 0.45–0.87 0.0048
Adjusted for propensity score 0.68 0.50–0.93 0.0164
Adjusted for covariates and
propensity score
0.63 0.46–0.87 0.0054
CI  confidence interval; PCI  percutaneous coronary intervention.
Figure 1. Kaplan-Meier estimation of the survival rates within the first year after percutaneous coronary intervention (PCI).
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in this study. Regardless, renal insufficiency was an inde-
pendent predictor for mortality in our model even after
adjusting for all these factors. The explanation of the
mechanics of the survival benefits associated with beta-
blockers in these patients may warrant further exploration.
Traditionally, rotational atherectomy has been implicated
in post-procedure CK-MB elevation. Although the benefits
of beta-blockers did not appear to be mediated by myocar-
dial protection after an incidence of myonecrosis, beta-
blockade was associated with a significant mortality reduc-
tion at one year after rotational atherectomy. The
association between atherectomy use, beta-blocker use, and
mortality reduction may be confounded by factors such as
diffuse coronary and systemic atherosclerosis because pa-
tients with these lesion characteristics may derive a greater
benefit from the use of beta-blockers. In view of a greater
benefit of beta-blockers among patients with prior MI, prior
CABG, LVEF 35%, multi-vessel CAD, and multi-vessel
PCI than among without these factors, our study suggests
that the benefits of beta-blockers are largely proportional to
the extent of the cardiovascular disease burden in these
patients.
Observations from multivariate analysis. Importantly,
our study highlights the independent predictors for one-year
mortality after elective PCI. The factors were similar to the
ones reported from the National Heart, Lung, and Blood
Institute Percutaneous Transluminal Coronary Angioplasty
(NHLBI PTCA) Registry (24). Disappointingly, other
than beta-blocker and aspirin administration, which were
associated with survival benefit, many of these independent
risk factors are non-modifiable. Consistent with the other
reports (25,26), very low body mass index was noted to be
the most powerful predictor for mortality at one year in
contemporary PCI.
Study limitations. This study has limitations inherent to
any registry data. The use of beta-blockers at the time of
intervention was not randomized. Despite the use of the
conventional and appropriate statistical methods for adjust-
ing for the heterogeneity between the two groups and
physicians’ decisions to prescribe the drugs, beta-blocker use
may still be a surrogate marker for better care, and this may
contribute, in part, to a better outcome. In addition, the
duration of treatment with beta-blockers before the proce-
dure was unknown. However, the presence of an inadequate
beta-blockade before the procedure would lead only to an
underestimation of the benefit of beta-blockers. Similarly,
the compliance of beta-blockers after hospital discharge was
unrecorded. When we sampled our population systemically,
we noted that the correlation of pre-procedural beta-blocker
use and use at discharge was close to 90%. In addition, a
previous study of 3,831 patients reported that 90% of
patients continued to receive beta-blockers at six months
despite complete revascularization with PCI (11). More-
over, because our study was based on beta-blocker status at
the time of intervention, any crossover of beta-blocker use
between the two groups would lead to an underestimation
of the effect of beta-blockers in the reduction of mortality.
Conclusions. In summary, this large observational study
performed in the era of PCI demonstrated a survival benefit
at one year with the use of beta-blockers at the time of PCI,
and this benefit was present across the majority of the
patient subgroups. Because the aim of medical care is to
Figure 2. Independent predictors for mortality at one year after percutaneous coronary intervention. CAD  coronary artery disease; CI  confidence
interval; COPD  chronic obstructive pulmonary disease; LVEF  left ventricular ejection fraction.
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reduce mortality and morbidity of our patients, medical
therapy with beta-blockers and percutaneous coronary re-
vascularization should be considered as complementary
strategies.
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